NCQM — National Committee for Quality Management

Search NCQM

Industry reference

Pharmaceuticals & Biologics

Drug and biological product quality depends on a controlled relationship between the authorized product, manufacturing process and evidence of identity, strength, quality and purity. A quality system supports this relationship throughout the product life cycle.

A product-specific review

Move from scope to evidence

  1. Define the product and activity

    Identify the product authorization pathway, manufacturing activities and responsible establishments. Distinguish a drug product, active ingredient and biological product where their obligations differ. Record the authorized formulation, process and control strategy against which later evidence and changes will be assessed.

  2. Connect requirements to evidence

    Connect purchasing, material release, process validation, laboratory controls and batch disposition. Review deviations and out-of-specification results with their investigation and technical conclusions. An isolated passing result does not explain whether the process and laboratory controls were adequate for the batch.

  3. Review interfaces and changes

    Coordinate change review with the authorized product baseline and applicable reporting or submission requirements. Keep complaints, stability information and postmarket signals connected to manufacturing knowledge. A management system certificate is not a substitute for the relevant product authorization or current manufacturing obligations.

5 source profiles

Requirements and technical resources

Review the references relevant to your product and activity. This selected federal collection does not replace a separate review of applicable state, local or contractual requirements.

Federal regulationFDA

Biological Products: General Controls and Product Standards

21 CFR Parts 600 and 610; related licensure provisions in Part 601

Biological products combine manufacturing controls with product-specific evidence and licensure responsibilities. Parts 600 and 610 address general establishment matters, records and biological-product standards. Their application must be read with the licensing framework and any more specific product rules. Sterility, potency, identity and purity have distinct regulatory roles; a generic laboratory panel cannot establish the complete position for every biologic.

Pharmaceuticals & Biologics

Agency guidanceFDA

Drug Stability: FDA ICH Q1A(R2) Guidance

FDA guidance Q1A(R2), November 2003; 21 CFR 211.166

FDA’s final Q1A(R2) guidance describes a stability-data package for new drug substances and products within its scope. It addresses study design, batches, containers, storage conditions, testing intervals and evaluation. Stability evidence supports a retest period or shelf life and proposed storage instructions. The separate consolidated Q1 document checked for this brief is explicitly draft and must not be presented as a final replacement.

Pharmaceuticals & Biologics

Federal regulationFDA

Finished Pharmaceuticals: Current Good Manufacturing Practice

21 CFR Parts 210 and 211

Drug CGMP establishes the systems and controls used to produce medicines with their intended identity, strength, quality and purity. Part 210 provides general applicability, while Part 211 addresses finished pharmaceuticals. Responsibilities extend beyond finished-product testing to the quality unit, materials, facilities, production, laboratory operations, packaging and records. Product and activity-specific provisions must be considered alongside these general requirements.

Pharmaceuticals & Biologics

Federal regulationFDA

Human Cells and Tissues: Part 1271 and Tissue Practices

21 CFR Part 1271; PHS Act sections 351 and 361

Part 1271 addresses human cells, tissues, and cellular and tissue-based products, or HCT/Ps. It establishes requirements concerning registration, donor eligibility, tissue practices and records. Regulatory treatment depends on the product and its intended use, including minimal manipulation and homologous use. Meeting registration requirements does not establish that a product qualifies for regulation solely under section 361 or has FDA marketing approval.

Pharmaceuticals & BiologicsMedical Devices & Diagnostics

Statutory or administrative frameworkFDA

OTC Drugs: Monographs and Administrative Orders

FD&C Act section 505G; applicable OTC monograph administrative orders

The OTC monograph pathway permits qualifying nonprescription drugs to be marketed without an approved drug application when section 505G and other applicable requirements are met. Administrative orders establish or change the relevant conditions. The assessment concerns a therapeutic category, active ingredients, uses, doses, routes, labeling and testing, not simply whether a product is sold without a prescription.

Pharmaceuticals & BiologicsCosmetics & Personal Care

Build a defensible review record

Identify the product configuration, the controlling provision and edition, the evidence required and the person authorized to make the decision. Keep a reason for exclusions and unresolved questions alongside confirmed requirements.

Revisit the record when design, materials, suppliers, software, claims or the applicable source changes. An earlier report remains useful only to the extent that it supports the current configuration and requirement.

Practice guidance